WUXI, China, June 30, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi — Drug Substance Facility 2 (MFG2) and Drug Product Facility 1 (DP1) — together with its Drug Product Packaging Center (DPPC), have received GMP certification from Brazil's Agência Nacional de Vigilância Sanitária (ANVISA). The certification positions WuXi Biologics to provide end‑to‑end commercial manufacturing services — covering both drug substance and drug product — for an anti-PD-L1 monoclonal antibody used in cancer immunotherapy.

Based on the five-day inspection, MFG2, DP1 and DPPC successfully passed ANVISA's assessment with zero findings. The inspection results demonstrate WuXi Biologics' robust quality management system, mature GMP execution, and efficient cross-functional collaboration, while verifying the company's comprehensive capabilities to support client needs for global commercial manufacturing and supply.

Within WuXi Biologics' global GMP manufacturing network, MFG2, DP1 and DPPC collectively provide integrated, end-to-end capabilities spanning large-scale biologics drug substance manufacturing, clinical and commercial drug product fill-finish, and customized packaging, meeting regulatory requirements across major markets worldwide. Together, these capabilities enable seamless manufacturing and reliable commercial supply for innovative biologic therapies.

Dr. Chris Chen, CEO of WuXi Biologics, commented, "Receiving ANVISA GMP certification reflects WuXi Biologics' continued commitment to global quality and compliance standards, and further validates our international standards across facilities, quality systems, and GMP execution. Looking ahead, we will continue to leverage our world-class quality system and end-to-end manufacturing capabilities to enable clients' global commercialization strategies, including entry into Latin America. By accelerating the delivery of high-quality, affordable biologics, we are helping to broaden access to innovative biologics for patients around the world."

WuXi Biologics has consistently demonstrated a proven track record of adherence to the industry's rigorous quality standards. As of the end of 2025, it has successfully passed 46 regulatory inspections, including 22 conducted by the FDA and EMA, and secured 136 facility license approvals. The company also holds an industry-leading record, achieving a 100% pass rate for FDA Pre-License Inspection (PLI). In addition, WuXi Biologics has passed more than 1,800 GMP quality audits by global clients, including over 230 audits by EU Qualified Persons. Currently, the company operates 15 GMP-certified drug substance and drug product facilities within its global network. Its world-class quality and compliance capabilities underpin long-standing trust from clients worldwide.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics — from concept to commercialization — for the benefit of patients worldwide*.

With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients' needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of April 30, 2026, WuXi Biologics is supporting 982 integrated client projects, including 78 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com. 

*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)

*The winner of the "2026 Best Contract Development & Manufacturing Organization Award" (ABEA)

Contacts
Business
[email protected] 

Media
[email protected]

SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, and Eli Lilly and Company (NYSE: LLY) today jointly announced that they have entered into a distribution and promotion agreement regarding Lilly's CDK4 & 6 inhibitor Verzenios^® (abemaciclib) in mainland China:

• Innovent will be responsible for the importation, marketing, distribution and promotion of Verzenios^® (abemaciclib) in mainland China;
• Lilly will continue to be responsible for manufacturing, supply, and development for the product.

Verzenios^® (abemaciclib), developed by Lilly, is a CDK4 & 6 inhibitor that has been approved in China for multiple indications, including:

(1) Early Breast Cancer: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.
(2) Locally Advanced or Metastatic Breast Cancer:
a) For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer:

• In combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women.
• In combination with fulvestrant for patients who have experienced disease progression following prior endocrine therapy.

b) In combination with imlunestrant: for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer who have previously received endocrine therapy.

The product was included in the National Reimbursement Drug List (NRDL) Class B in 2021, becoming the first CDK4 & 6 inhibitor covered by national reimbursement in China. In 2025, it successfully renewed its NRDL listing, achieving full coverage across both early and advanced breast cancer indications.

Under the agreement, Innovent will hold sole commercialization rights for Verzenios^® (abemaciclib) in mainland China, while Lilly, as the Marketing Authorization Holder (MAH), will continue to be responsible for manufacturing, supply, and ongoing product development. This collaboration combines Innovent's experienced oncology commercialization team and extensive market reach in China with Lilly's expertise in innovative medicine development and lifecycle management, further enhancing access to this important therapy and benefiting more breast cancer patients across the country.

Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent, stated: "We are delighted to further deepen our strategic partnership with Lilly through this eighth collaboration, bringing the number of our partnered, on-market products in China to seven. This also marks the 19^th product in Innovent's portfolio. Enhancing patient access to high-quality, innovative medicines has always been at the core of Innovent's mission. Leveraging our established commercial infrastructure and strong market presence in China, we remain focused on addressing critical unmet needs in major oncology indications. Breast cancer, one of the most prevalent and life–threatening malignancies among women, is a strategic priority within Innovent's oncology portfolio. Through this commercial collaboration with Lilly on Verzenios^® (abemaciclib) – backed by its robust clinical efficacy, comprehensive labeled indications and national reimbursement coverage – we are expanding our presence in this area, laying a solid foundation for our pipeline development and market expansion deliver lasting benefits to patients in breast cancer."

Huzur Devletsah, Lilly Group Vice President and China General Manager, said: "For 150 years, Lilly has remained committed to putting health above all, advancing human health through scientific innovation and expanding access through collaboration. This agreement for Verzenios^® (abemaciclib) is an important step in strengthening patient access in China, combining Lilly's global R&D expertise with Innovent's commercialization capabilities in China. Looking ahead, Lilly will continue to advance its oncology efforts in China. Since the beginning of this year, we have secured approvals for one new medicine (with two indications) and two new additional indications for on market products in China, including Inluriyo^®, which has become the first and currently only approved precision therapy in China only targeting ESR1-mutated advanced breast cancer, accelerating the introduction of globally innovative therapies and addressing unmet medical needs."

About Innovent
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 19 products in the market. It has 1 asset in NMPA NDA review, 5 assets in Phase 3 or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Takeda, Pfizer, Roche, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn. 

Statement:
1) Innovent does not recommend the use of any unapproved drug (s)/indication (s).
2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo), Pirtobrutinib (Jaypirca) and abemaciclib (Verzenios) were developed by Eli Lilly and Company.
Disclaimer: Innovent does not recommend any off-label usage.

About Lilly 
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.

Forward-Looking Statements of Innovent Biologics
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

LENOVO GROUP (00992.HK) is not only a long-term agreement customer of Micron Technology, Inc. (MU.US), but has also signed long-term supply agreements for storage products with Samsung and SK Hynix, Shanghai Securities News cited sources as saying.

LENOVO GROUP's China infrastructure business is radically raising its server business growth expectations, according to hearsay. The company previously set a server business target of RMB100 billion for FY2027/2028.

Based on currently executing orders, the confirmable revenue delivery scale from only two major customers next year has already approached RMB200 billion.
~

AASTOCKS Financial News
Website: www.aastocks.com

Samsung Electronics, SK Hynix and Micron Technology, Inc. (MU.US) are facing an antitrust lawsuit in the US. The three companies are accused of manipulating DRAM prices by deliberately reducing the supply of conventional DRAM under the pretext of expanding production of HBM, thereby driving up prices.

The plaintiffs include 14 US consumers and three small and medium-sized PC assembly and distribution companies. They alleged that the three companies have systematically restricted DRAM supply since 2022, giving rise to prices surging by about 700% over the past four years.

The plaintiffs contend that the defendants used inventory management as a justification to cut output, while in reality artificially creating shortages to raise prices.
~

AASTOCKS Financial News
Website: www.aastocks.com

倫敦2026年6月29日 /美通社/ -- 6月22日，「倫敦氣候行動周」期間，全球循環經濟倡導者艾倫•麥克阿瑟基金會與寧德時代、寶馬、雷諾、沃爾沃、谷歌、小米等企業宣佈共同發起「全球能源循環經濟聯盟」，並啟動《電池可循環設計指南》開發計劃。這是寧德時代在「全球能源循環計劃」（GECC）框架下，與基金會等合作夥伴共同推進的最新進展，標誌著電池循環經濟由願景邁入標準建設與商業實踐階段。

作為倫敦氣候行動周開幕旗艦活動「氣候創新論壇」的重要專題論壇之一，「循環經濟與零廢棄論壇」圍繞零碳轉型、循環經濟與氣候韌性等議題，匯聚來自全球的政府、企業、金融機構及社會組織代表，共同探討氣候行動與產業轉型路徑。寧德時代副總經理、董事會秘書蔣理，章魚能源投資總監兼聯合投資負責人王壚，谷歌全球氣候業務總監維魯沙利•高德，思愛普首席營銷官斯蒂芬•詹米森，國際能源署高級分析師肖邦•迪爾，以及艾倫•麥克阿瑟基金會關鍵礦產項目執行負責人翁文妤等出席了本次活動。

艾倫•麥克阿瑟基金會氣候項目負責人米蘭達•施尼特格認為，循環經濟是應對全球生產與消費環節45%的碳排放的關鍵路徑，也是氣候行動的重要槓桿。

「循環經濟不是電池產業增長的約束，而是形成更可持續、更可複製的經營模式。」寧德時代副總經理、董事會秘書蔣理表示，電池產業未來可以通過延長電池壽命、推動材料回收，全生命週期減碳，提升供應鏈韌性。

此次發起的「全球能源循環經濟聯盟」聚焦循環商業模式的規模化推廣，圍繞電池使用歷史、健康狀態、衰減數據、回收責任等關鍵維度建立統一評價依據，以幫助車企、物流企業、投資機構和政策制定者更準確評估電池資產價值和運營風險。艾倫•麥克阿瑟基金會將作為合作平台，推動產業鏈協作。

同時啟動的《電池可循環設計指南》將圍繞電池全生命週期，從易拆解、可診斷、可維修、可再製造和材料回收等環節建立設計原則與評價依據，覆蓋乘用車、商用車等不同交通應用場景，為整車企業、採購方、投資機構和監管部門提供行業參考。目前，相關工作已啟動，完整指南計劃於2027年發佈。

當前，產業亟需從單純擴大產能，轉向深耕全生命週期價值。2025年，寧德時代成為全球首家實現核心運營碳中和的新能源科技公司，旗下所有電池工廠成為「零碳工廠」，碳排放強度較2022年下降77%。自2023年以來，寧德時代已實施超過1000個節能項目，通過提升能效、推動工藝電氣化和擴大低碳電力使用，持續降低運營碳足跡。

製造端減碳只是第一步，電池價值鏈更大的減碳挑戰來自價值鏈。包括礦產開採與原材料加工在內的價值鏈碳排放是核心運營排放的五倍。目前，再生材料已帶動材料碳排放強度同比下降32%。控股子公司邦普2025年回收處理廢舊電池及材料21萬噸，鎳、鈷、錳回收率達99.6%，約80%的再生材料直接回用於寧德時代電池生產。

倫敦氣候週期間，寧德時代還與英國最大能源公司章魚能源宣佈將成立合資公司，共同建設歐洲重卡換電網絡。章魚能源創始人、首席執行官格雷格•傑克遜表示，換電、共享和智能調度等模式有助於提高電池利用效率，減少對新礦開採的依賴。

「全球能源循環計劃」是首個由中國企業發起的循環經濟公益項目，也是首個覆蓋新能源產業全產業鏈、政府與學術機構等多方力量的協作網絡，致力於推動電池循環經濟全面落地，助力新電池生產徹底擺脫對原生礦產資源的依賴。未來，各方將持續推動循環經濟路線圖在不同國家和地區開展試點，探索可複製、可推廣的循環解決方案。

LONDON, June 29, 2026 /PRNewswire/ -- On June 22, CATL and the Ellen MacArthur Foundation announced two new initiatives together with BMW, Renault, Volvo, Google, Xiaomi and other industry leaders and stakeholders, at the Climate Innovation Forum, the flagship event of London Climate Action Week 2026, through CATL's Global Energy Circularity Commitment (GECC), developed in strategic partnership with the Ellen MacArthur Foundation. The initiatives include circular battery design guidelines to embed circularity across the full battery lifecycle, and a business coalition to accelerate the policy, investment and commercial conditions needed to make circular business models the industry norm.

By 2040, the global battery recycling market alone is projected to exceed RMB 1.2 trillion, creating more than 10 million jobs, while the International Energy Agency projects demand for battery-critical minerals will increase fivefold over the same period. Meeting that demand sustainably will require not only greater recycling capacity, but common design standards and business models that keep materials in productive use for longer.

CATL became the first battery manufacturer to achieve carbon neutrality across its core operations in 2025, certified under ISO 14068-1, with full value-chain carbon neutrality targeted by 2035. Much of the remaining challenge lies in mining and raw material processing rather than manufacturing. Circularity will play a central role in meeting future demand without proportional increases in virgin material extraction. The initiatives announced aim to help build the common frameworks needed to accelerate that transition.

Earlier the same day, at Octopus Energy's Energy Tech Summit, CATL and Octopus Energy announced Europe's first battery-swapping joint venture, targeting 300,000 electric trucks and 30 hubs across Europe by 2035, with the first UK hubs scheduled to open in 2027. The partnership demonstrates the type of commercially viable circular business model the coalition aims to accelerate.

Miranda Schnitger, Climate Lead at the Ellen MacArthur Foundation: "Circular economy approaches were key to tackling the 45% of emissions that come from how we produce and consume."

Jiang Li, Vice President and Board Secretary, CATL: "Last year we set the direction: decouple battery growth from virgin material extraction. Today, the industry is beginning to build the common rules that will help deliver it. That is not only a climate opportunity, but an industrial one."

Greg Jackson, Founder and CEO, Octopus Energy Group: "By designing batteries to be swapped, optimised, shared and reused thousands of times, we can squeeze every drop of value out of the materials we already have, rather than digging up more. That's why our battery-swapping joint venture with CATL matters; we are taking the world's best hardware, combining it with smart energy tech to make it cheaper and more flexible, and building a completely self-sustaining transport network."

Initiative I: Circular Battery Design Guidelines

The circular battery design guidelines establish a common methodology for circular battery design across a range of mobility applications. As a founding partner, CATL brings practical experience from battery manufacturing, recycling and service operations to support their development. The methodology is intended to inform procurement standards, investor frameworks and future regulatory discussions, including the evolution of European battery policy.

Developed to address fragmentation across approaches to repair, second life and recycling, the guidelines provide a shared basis for comparing circular performance across the market. They aim to help buyers evaluate products, investors assess long-term value, and policymakers reference a consistent framework.

The Ellen MacArthur Foundation provides a neutral platform through which companies across the battery value chain can develop shared principles that no single organisation could establish alone. The working group is now underway, with publication planned for 2027.

Initiative II: Business Coalition for Circular Business Models

The coalition for circular business models is a policy and industry platform established to accelerate the adoption of circular business models across mobility and energy. With battery swapping already operating across more than 1,650 stations in 127 Chinese cities, the focus is shifting from demonstrating technical feasibility to creating the commercial, regulatory and financing conditions required for international scale.

CATL contributes practical experience through its battery-as-a-service and battery-swapping businesses, including the expanding Choco-Swap and QIJI networks, providing operational insights that can support wider deployment globally.

The coalition also seeks to establish common approaches for evaluating circular battery assets, including service history, degradation data and second-life value, providing investors, fleet operators and policymakers with greater confidence and reducing market uncertainty.

CATL Advances Circular Battery Systems

CATL continues to scale circularity across its operations. In 2025, Brunp Recycling processed 210,000 tonnes of end-of-life batteries, recovering 99.6% of nickel, cobalt and manganese, with 80% of recovered materials returning directly into CATL's battery production.

Rather than treating recycling as the end of a product's life, CATL integrates circularity into battery design, manufacturing, use and recovery as a connected system.

Furthermore, CATL is accelerating the commercialization of sodium-ion batteries, with plans to deliver its first sodium-ion energy storage systems to customers starting this September. This initiative expands the energy storage technology roadmap beyond lithium, cobalt, and nickel, enhancing material supply resilience and cost stability.

CHANGSHA, China, June 29, 2026 /PRNewswire/ -- At the Seventh Science and Technology Innovation Conference hosted by Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion"), the ZT82J straight-boom aerial work platform received an Outstanding Flagship Product Award. With a maximum working height of 82.3 meters, it is the world's tallest model in its category, addressing demand for aerial work equipment capable of operating above 80 meters and meeting the stringent safety demands of major infrastructure projects worldwide.

Behind this achievement is the persistent effort of product manager He Jipeng and his team at the Aerial Work Platform R&D Center, who drove the ZT82J from concept to mass production through design, testing, process implementation, and cross‑departmental coordination.

The core challenge from the outset was balancing two hard constraints, overall dimensions and total weight, while completing the structural layout. The R&D scope covered an ultra‑long, specially shaped lightweight boom, a box‑type turntable, and a high‑capacity chassis, aiming to reduce weight while significantly improving structural rigidity to ensure bending and torsional resistance under 82.3‑meter lifting conditions and suppress platform sway.

With no mature industry example and benchmark to follow, the team encountered bottlenecks including insufficient layout space, excessive weight, and inadequate rigidity. Weight reduction, overall dimensions and structural rigidity involved competing requirements, making it extremely difficult to find the optimal balance.

After over ten rounds of simulation, the team developed and refined a proprietary multi-edge boom cross-section and evaluated multiple telescoping configurations to optimize the overall structure. This ensured vertical and lateral stiffness while balancing weight-reduction targets with structural capacity within fixed limits.

Building on the lightweight boom, He Jipeng and the team integrated turntable and chassis optimization. Simulation identified weak stress points, precisely optimized plate cross‑sections, and reduced redundant steel while maintaining safety margins, achieving a lightweight upgrade, enhancing anti‑fatigue and anti‑overturning performance, and completing a structural breakthrough for ultra‑high working height equipment.

To support the project, Zoomlion assembled a task force of structural, hydraulic, and electronic control experts, backed by a simulation team and dedicated testing facilities, ensuring seamless coordination from design to production.

"This award recognizes our team's progress in developing ultra-high-reach aerial work platforms and demonstrates the capabilities of Zoomlion's high-end construction machinery," He Jipeng said. "It has also greatly boosted our confidence to continue pushing the boundaries of innovation and breaking through technical barriers."

GUANGZHOU, China, June 29, 2026 /PRNewswire/ -- MINISO Group Holding Limited (NYSE: MNSO; HKEX: 9896) ("MINISO", "MINISO Group" or the "Company"), a global high-growth value retailer offering a variety of trendy lifestyle products featuring distinctive IP designs, today announced that, the board of directors of the Company (the "Board") authorized and approved a new share repurchase program (the "2026 Share Repurchase Program"), under which the Company may repurchase up to HKD2 billion in value of its outstanding ordinary shares (the "Shares") and/or American depositary shares (the "ADSs") (each representing four Shares) from the open market over a 12-month period starting from June 30, 2026. The Company expects to fund the repurchases under the 2026 Share Repurchase Program from surplus cash on its balance sheet.

The Board has full confidence in the Company's business outlook and prospects, and believes that the current share price of the Company has been below its intrinsic value. Under the HK$2 billion share repurchase program adopted by the Company on August 30, 2024 and extended until June 30, 2026 (the "Extended 2024 Share Repurchase Program"), the Company has repurchased the Shares and/or the ADSs with an aggregate value of approximately HK$1.37 billion on the open market. By implementing the 2026 Share Repurchase Program, the Company aims to promote the interests of its shareholders ("Shareholders"), balance MINISO Group's fast growth and its commitment to bringing stable and foreseeable return to the Shareholders.

The Company's proposed repurchases under the 2026 Share Repurchase Program may be made from time to time on the open market at prevailing market prices, in privately negotiated transactions, in block trades, and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations.

The Company shall conduct the repurchases by exercising its powers under the repurchase mandate granted or to be granted to the Board pursuant to the resolutions of the Shareholders passed at the annual general meeting of the Company each year to repurchase the Shares not exceeding 10% of the total number of the issued Shares (excluding any treasury Shares) as at the date of such annual general meeting (the "Share Repurchase Mandate"), with each mandate to expire upon whichever is the earliest of: (a) the conclusion of the next annual general meeting of the Company; (b) the expiration of the period within which the next annual general meeting of the Company is required by the memorandum and articles of the association of the Company or by any applicable laws to be held; and (c) the date on which the authority given under the ordinary resolution approving the Share Repurchase Mandate is revoked or varied by an ordinary resolution of the Shareholders.

During the period from June 30, 2026 to the date of holding the upcoming annual general meeting of the Company in 2027, the Company will conduct the repurchases under the Share Repurchase Mandate granted by the Shareholders on June 18, 2026, and for the remaining period under the 2026 Share Repurchase Program, the Company will conduct the repurchases under the Share Repurchase Mandate to be granted by the Shareholders at the upcoming annual general meeting of the Company, subject to the approval of the Shareholders and the general mandate conditions as specified above. It is the intention of the Board to implement the 2026 Share Repurchase Program during the 12-month period only in such a way and only to such an extent that would not cause a mandatory general offer obligation to arise under Rule 26 of the Hong Kong Code on Share Buy-backs.

The Company will conduct the proposed share repurchases in compliance with the memorandum and articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Codes on Takeovers and Mergers and Share Buy-backs, the Companies Law of the Cayman Islands and all applicable laws and regulations to which the Company is subject to.

The Company may cancel such repurchased Shares or hold them as treasury Shares, subject to market conditions and MINISO Group's capital management needs at the relevant time of the repurchases.

The Board believes that the current financial resources of the Company would enable it to implement the share repurchases without causing any material impact on its working capital.

The Board will review the 2026 Share Repurchase Program periodically, and may authorize adjustment of its terms and size.

Shareholders and potential investors of the Company should note that any repurchase may be done subject to market conditions and at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any repurchase. Shareholders and potential investors of the Company should therefore exercise caution when dealing in the Shares.

About MINISO Group

MINISO Group is a global high-growth value retailer offering a variety of trendy lifestyle products featuring distinctive IP designs. Since opening our first store in Chinese mainland in 2013, the Company has successfully built two brands – "MINISO" and "TOP TOY". The Company's flagship brand "MINISO" has grown into a globally recognized retail brand that offers a frequently-refreshed assortment of lifestyle products through an extensive store network worldwide. The Company's products cover diverse consumer needs and consumers are drawn to MINISO for our products' trendiness, creativeness, high quality and affordability. For more information, please visit https://ir.miniso.com/.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "anticipate", "aim", "estimate", "intend", "plan", "believe", "is/are likely to", "potential", "continue" or other similar expressions. Among other things, the quotations from management in this announcement, as well as MINISO's strategic and operational plans, contain forward-looking statements. MINISO may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC") and The Stock Exchange of Hong Kong Limited (the "HKEX"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about MINISO's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: MINISO's mission, goals and strategies; future business development, financial conditions and results of operations; the expected growth of the retail market and the market of branded variety retail of lifestyle products in China and globally; expectations regarding demand for and market acceptance of MINISO's products; expectations regarding MINISO's relationships with consumers, suppliers, Retail Partners, local distributors, and other business partners; competition in the industry; proposed use of proceeds; and relevant government policies and regulations relating to MINISO's business and the industry. Further information regarding these and other risks is included in MINISO's filings with the SEC and the HKEX. All information provided in this press release and in the attachments is as of the date of this press release, and MINISO undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Investor Relations Contact:

MINISO Group Holding Limited
Email: [email protected]
Phone: +86 (20) 36228788 Ext.8039

The South Korean stock market has experienced wild swings recently, with circuit breaker triggered five times so far this year. The Korea Exchange has postponed the launch of weekly options products linked to four heavyweight stocks, including Samsung Electronics and SK Hynix.

Since the start of this year, about one-fifth of trading days in the MSCI Korea Index have marked single-day moves exceeding 5%, The Wall Street Journal reported. Mathieu Racheter, head of equity research at Julius Baer, said recent market movements have sounded an important alarm over concentration risk. When investor positioning becomes excessively crowded, markets inevitably enter periods of heightened volatility.

Retail investors borrowed funds to buy shares of the two major index heavyweights, Samsung Electronics and SK Hynix. This could expose individual investors to margin calls. With market risk highly concentrated in just two stocks, institutional investors may also withdraw capital, potentially amplifying downside pressure on share prices.

Compared with other markets along the AI supply chain, the concentration level in the South Korean market is strikingly high. Currently, SK Hynix and Samsung Electronics together account for a record 60% of the Korean Kospi. In the US Nasdaq market, the two largest companies by market cap, NVIDIA Corporation (NVDA.US) and Apple Inc. (AAPL.US), together account for only about 20% of the index.

Goldman Sachs analysts Timothy Moe and John Kwon noted that, under the diversification requirements stipulated by the US Investment Company Act, a further 1% hike in the combined weighting of Samsung Electronics and SK Hynix could trigger approximately USD2 billion in outflows from foreign investors in the Korean market.

Goldman Sachs added that substantial inflows into leveraged exchange-traded funds (ETF), coupled with rising options trading and margin financing by retail investors, created a fragile structural environment. In such conditions, daily price swings in the equity market derailed immensely from levels justified by corporate fundamentals.
~

AASTOCKS Financial News
Website: www.aastocks.com

AS Watson Group, the world’s largest international health and beauty retailer, announced the appointment of 31 global strategic technology partners to accelerate the next phase of its AI-powered O+O (Offline plus Online) transformation. Strategic partners include Oracle Corporation (ORCL.US), Microsoft Corporation (MSFT.US), and NCR Voyix.

Malina Ngai, Group CEO of AS Watson, said that AI is not a standalone technology layer. It is a core capability that runs across the organisation. The Group's priority is to use AI to remove friction, accelerate execution and help its people focus on creating value for customers. Its 31 global technology partners play a critical role in this journey. Together, they are combining data, technology and human judgement to build a more agile, scalable and future ready organisation.
~

AASTOCKS Financial News
Website: www.aastocks.com